Evidence map›Paper›PMID 34065861›Full record

ArticleInternational journal of molecular sciences2021

Antimicrobial Activities of LL-37 Fragment Mutant-Poly (Lactic-Co-Glycolic) Acid Conjugate against

Takeshi Mori, Miyako Yoshida, Mai Hazekawa, Daisuke Ishibashi, Yoshiro Hatanaka, Toshihiro Nagao, Rie Kakehashi, Honami Kojima, Rio Uno, Minoru Ozeki and 4 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in microbiology · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Takeshi MoriFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Miyako YoshidaFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Mai HazekawaDepartment of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka City 814-0180, Japan.
Daisuke IshibashiDepartment of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka City 814-0180, Japan.
Yoshiro HatanakaOsaka Research Institute of Industrial Science and Technology, 1-6-50 Morinomiya, Joto-ku, Osaka City 536-8553, Japan.
Toshihiro NagaoOsaka Research Institute of Industrial Science and Technology, 1-6-50 Morinomiya, Joto-ku, Osaka City 536-8553, Japan.
Rie KakehashiOsaka Research Institute of Industrial Science and Technology, 1-6-50 Morinomiya, Joto-ku, Osaka City 536-8553, Japan.ORCID 0000-0003-4348-620X
Honami KojimaFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Rio UnoFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Minoru OzekiFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Ikuo KawasakiFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Taku YamashitaFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Junichi NishikawaFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Takahiro UchidaFaculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien 9-Bancho, Nishinomiya City 663-8179, Japan.
Mukogawa Women's University · JPOsaka Research Institute of Industrial Science and Technology · JPFukuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various peptides and their derivatives have been reported to exhibit antimicrobial activities. Although these activities have been examined against microorganisms, novel methods have recently emerged for conjugation of the biomaterials to improve their activities. Here, we prepared CKR12-PLGA, in which CKR12 (a mutated fragment of human cathelicidin peptide, LL-37) was conjugated with poly (lactic-co-glycolic) acid (PLGA), and compared the antimicrobial and antifungal activities of the conjugated peptide with those of FK13 (a small fragment of LL-37) and CKR12 alone. The prepared CKR12-PLGA was characterized by dynamic light scattering and measurement of the zeta potential, critical micellar concentration, and antimicrobial activities of the fragments and conjugate. Although CKR12 showed higher antibacterial activities than FK13 against

Indexed as

Anti-Infective AgentsAntimicrobial Cationic PeptidesCandida albicansCathelicidinsEscherichia coliHumansMicrobial Sensitivity TestsMicrobial ViabilityMicroscopy, Electron, TransmissionMutationPolylactic Acid-Polyglycolic Acid CopolymerStaphylococcus aureusAnti-Infective AgentsAntimicrobial Cationic PeptidesCathelicidinsPolylactic Acid-Polyglycolic Acid Copolymerantimicrobial peptideconjugation with poly (lactic-co-glycolic) acidmutant peptidescanning electron microscopytransmission electron microscopy

Identifiers

PMID34065861
PMCPMC8151943
OpenAlexW3160055149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.